Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

5.03

Margin Of Safety %

Put/Call OI Ratio

0.1

EPS Next Q Diff

-0.03

EPS Last/This Y

-1.59

EPS This/Next Y

-0.17

Price

5.42

Target Price

14.98

Analyst Recom

1

Performance Q

15.29

Relative Volume

0.78

Beta

0.82

Ticker: IMTX



19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02IMTX6.020.160.093054
2025-06-03IMTX5.880.16999.993049
2025-06-04IMTX5.760.151.503029
2025-06-05IMTX5.790.15999.993049
2025-06-06IMTX5.940.160.003055
2025-06-09IMTX5.990.150.003068
2025-06-10IMTX5.950.150.003078
2025-06-11IMTX5.960.150.083080
2025-06-12IMTX6.160.150.003376
2025-06-13IMTX6.140.150.003392
2025-06-16IMTX6.10.150.073400
2025-06-17IMTX6.140.150.163415
2025-06-18IMTX5.850.160.633406
2025-06-20IMTX5.610.1614.713407
2025-06-23IMTX5.410.1614.713407
2025-06-24IMTX5.440.1436.673206
2025-06-25IMTX5.470.102.503100
2025-06-26IMTX5.590.10999.993096
2025-06-27IMTX5.430.100.003086
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1



19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02IMTX6.01-92.6- -1.40
2025-06-03IMTX5.88-92.6- -1.40
2025-06-04IMTX5.75-92.6- -1.40
2025-06-05IMTX5.78-93.4- -1.43
2025-06-06IMTX5.95-93.4- -1.43
2025-06-09IMTX6.00-93.4- -1.43
2025-06-10IMTX5.94-93.4- -1.43
2025-06-11IMTX5.95-93.4- -1.43
2025-06-12IMTX6.14-93.4- -1.43
2025-06-13IMTX6.14-93.4- -1.43
2025-06-16IMTX6.10-93.4- -1.43
2025-06-17IMTX6.14-93.4- -1.43
2025-06-18IMTX5.85-93.4- -1.43
2025-06-20IMTX5.61-93.4- -1.43
2025-06-23IMTX5.43-93.4- -1.43
2025-06-24IMTX5.45-93.4- -1.43
2025-06-25IMTX5.47-93.4- -1.43
2025-06-26IMTX5.58-93.4- -1.43
2025-06-27IMTX5.42-93.4- -1.43
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1



18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02IMTX0.002.145.77
2025-06-03IMTX0.002.145.77
2025-06-04IMTX0.002.145.77
2025-06-05IMTX0.002.145.77
2025-06-06IMTX0.002.145.77
2025-06-09IMTX0.002.165.77
2025-06-11IMTX0.002.165.68
2025-06-12IMTX0.002.165.72
2025-06-13IMTX0.002.165.72
2025-06-16IMTX0.002.165.72
2025-06-17IMTX0.002.165.72
2025-06-18IMTX0.002.165.72
2025-06-19IMTX0.002.165.72
2025-06-20IMTX0.002.165.72
2025-06-24IMTX0.002.165.72
2025-06-25IMTX0.002.165.72
2025-06-26IMTX0.002.165.03
2025-06-27IMTX0.002.165.03
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS​

-0.35

Avg. EPS Est. Current Quarter

-0.36

Avg. EPS Est. Next Quarter

-0.38

Insider Transactions

Institutional Transactions

2.16

Beta

0.82

Average Sales Estimate Current Quarter

13

Average Sales Estimate Next Quarter

13

Fair Value

Quality Score

42

Growth Score

33

Sentiment Score

36

Actual DrawDown %

70.6

Max Drawdown 5-Year %

Target Price

14.98

P/E

Forward P/E

PEG

P/S

4.25

P/B

1.14

P/Free Cash Flow

EPS

-0.23

Average EPS Est. Cur. Y​

-1.43

EPS Next Y. (Est.)

-1.6

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-14.75

Relative Volume

0.78

Return on Equity vs Sector %

-28.1

Return on Equity vs Industry %

-10.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.08

EBIT Estimation

Immatics N.V.
Sector: Healthcare
Industry: Biotechnology
Employees: 646
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
stock quote shares IMTX – Immatics N.V Stock Price stock today
news today IMTX – Immatics N.V stock forecast ,stock prediction 2023 2024 2025
marketwatch IMTX – Immatics N.V yahoo finance google finance
stock history IMTX – Immatics N.V invest stock market
stock prices IMTX premarket after hours
ticker IMTX fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Facebook-f Twitter Tiktok Instagram Youtube

Get Started

About